腹膜透析の世界市場：2024年～2031年

レポート概要

腹膜透析の世界市場は、2023年の52億米ドルから2031年には83億米ドルに達し、予測期間2024～2031年のCAGRで6.0%の成長が予測されています。

腹膜透析は、腎臓が血液を効果的にろ過できない腎不全の治療法です。腹膜透析は、腹膜がフィルターとして機能する胃の部分（腹部）にチューブを通して洗浄液を流すものです。一定時間後、ろ過された液体は廃棄されます。腹膜透析は、体外で血液を機械でろ過する血液透析とは異なります。治療は自宅、職場、旅行先などで行うことができますが、腎不全のすべての人がこの治療の恩恵を受けられるわけではありません。腹膜透析を成功させるには、熟練したハンドケアと信頼できる介護者が必要です。

市場力学：

促進要因と抑制要因

慢性腎臓病の有病率の上昇

世界のESRDおよびCKDの罹患率の上昇は、主要な促進要因の1つです。透析を必要とする患者の増加に伴い、治療の選択肢としての腹膜透析（PD）の需要も増加しています。

例えば、CDC 2023によると、米国成人の14％、355億人が慢性腎臓病（CKD）を患っていると報告されています。有病率は年齢、人種、民族によって異なります。CKDは65歳以上（34％）、非ヒスパニック系黒人（20％）、女性（14％）に多いです。また、非ヒスパニック系アジア人または白人の成人ではより一般的です。

さらに、2023年のISN-GKHAの報告書では、約8,500億人がCKDに罹患していると推定しています。不利な立場にある人々はより高いリスクを負っています。

熟練した専門家の不足

腹膜透析（PD）機器の市場成長は、厳しい政府規制、技術的失敗の増加、ヘルニアやカテーテル閉塞などの合併症、熟練した専門家の不足によって妨げられています。加えて、高齢者層における受容性や認知度の低さ、PDサイクラーの認知度の低さも一因となっています。

市場セグメンテーション分析

世界の腹膜透析市場は、製品タイプ、治療タイプ、エンドユーザー、地域によって区分されます。

製品タイプ別では、腹膜透析液が腹膜透析市場シェアの約43.3%を占めています。

製品タイプ別の腹膜透析液のシェアは約43.3％。腹膜透析液は透析液としても知られ、末期腎不全（ESRD）や重度の慢性腎臓病（CKD）患者の治療に不可欠です。電解質、ブドウ糖、その他の浸透圧剤を含むこれらの透析液は、半透膜フィルターとして機能するカテーテルを通して腹腔内に導入されます。透析液の主な役割は、血液から老廃物、余分な水分、毒素を取り除くことです。透析液中のグルコース濃度は、体液除去や老廃物除去の効率に大きく影響します。

例えば、2024年3月、インドのヘルスケア業界で有名なファリダバードを拠点とするMitra Industries社は、最新のイノベーションである、ほぼ中性のpHと低グルコース分解産物（GDP）を持つ3室構造の腹膜透析（PD）バッグを発表しました。この画期的な製品は、慢性腎臓病（CKD）患者にとって重要な治療法である腹膜透析を受けている患者のケアに革命を起こすことを目的としています。

地域別市場分析

北米は予測期間を通じて市場シェア全体の約38.4%を占めると推定される

北米は、腎不全と慢性腎臓病の有病率の増加に加え、医療費の増加、政府の取り組み、可処分所得が業界の成長に寄与していることから、予測期間を通じて市場全体の約38.4%のシェアを占めると推定・予測されます。さらに、糖尿病と肥満は腎臓障害の一因となっています。

例えば、国立糖尿病・消化器腎臓病研究所によると、慢性腎臓病（CKD）は米国成人の7人に1人以上、推定370億人に1人が罹患しています。腎臓病を発症するその他の危険因子には、心臓病や腎不全の家族歴などがあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 慢性腎臓病の有病率の上昇
    • デバイスの進歩
  • 抑制要因
    • 熟練した専門家の不足
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 特許分析
• PESTLE分析
• SWOT分析
• DMIオピニオン

第6章 製品タイプ別

• 腹膜透析ソリューション
• 腹膜透析装置
• 腹膜透析カテーテル
• 透析セット
• その他

第7章 治療タイプ別

• APD
• CAPD

第8章 エンドユーザー別

• 在宅医療
• 病院
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Baxter International Inc
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Fresenius Medical Care AG & Co. KGaA
• Medtronic plc
• Nipro Corporation
• DaVita Inc.
• Diaverum
• B. Braun Melsungen AG
• Asahi Kasei Corporation
• Huaren Pharmaceutical Co., Ltd.
• NxStage Medical, Inc

第12章 付録

Report Overview

Global Peritoneal Dialysis Market reached US$ 5.2 billion in 2023 and is expected to reach US$ 8.3 billion by 2031, growing at a CAGR of 6.0% during the forecast period 2024-2031

Peritoneal dialysis is a treatment for kidney failure, where the kidneys cannot filter blood effectively. It involves a cleansing fluid flowing through a tube into the stomach area, or abdomen, where the peritoneum acts as a filter. After a set time, the filtered fluid is discarded. Peritoneal dialysis differs from hemodialysis, which filters blood outside the body in a machine. Treatments can be done at home, work, or while traveling, but not everyone with kidney failure can benefit from this treatment. Skilled hand care and a trusted caregiver are required for successful peritoneal dialysis.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of chronic kidney diseases

The rising incidence of ESRD and CKD worldwide is one of the primary drivers. As the number of patients requiring dialysis grows, the demand for peritoneal dialysis (PD) as a treatment option also increases.

For instance, according to the CDC 2023, reports that 14% of US adults, or 35.5 billion people, have chronic kidney disease (CKD). The prevalence varies by age, race, and ethnicity. CKD is more common in those aged 65 or older (34%), non-Hispanic Black adults (20%), and women (14%). It is also more prevalent in non-Hispanic Asian or White adults.

Moreover, the 2023 ISN-GKHA report estimates that approximately 850 billion people are affected by CKD. People from disadvantaged populations are at higher risk.

Lack of skilled professionals

The market growth of peritoneal dialysis (PD) devices is hindered by stringent government regulations, increasing technical failures, complications like hernias and catheter blockages, and a lack of skilled professionals. Additionally, low acceptance and awareness among the senior population and low awareness of PD cyclers are also contributing factors.

Market Segment Analysis

The global peritoneal dialysis market is segmented based on product type, treatment type, end user, and region.

The peritoneal dialysis solutions from the product type segment accounted for approximately 43.3% of the peritoneal dialysis market share

The peritoneal dialysis solutions from the product type segment accounted for approximately 43.3%. Peritoneal dialysis solutions, also known as dialysates, are essential in treating patients with end-stage renal disease (ESRD) or severe chronic kidney disease (CKD). These fluids, containing electrolytes, glucose, and other osmotic agents, are introduced into the peritoneal cavity through a catheter, acting as a semi-permeable filter. The primary function of the dialysis solution is to draw waste products, excess fluids, and toxins from the blood. The concentration of glucose in the solution significantly influences fluid removal and waste clearance efficiency.

For instance, in March 2024, Faridabad-based Mitra Industries, a renowned name in India's healthcare industry, unveiled its latest innovation- a triple-chambered peritoneal dialysis (PD) bag with a near-neutral pH and low glucose degradation products (GDPs). This groundbreaking product aims to revolutionize patient care for those undergoing peritoneal dialysis, a crucial therapy for Chronic Kidney Disease (CKD) patients.

Market Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to the increasing prevalence of kidney failures and chronic kidney diseases, along with rising healthcare costs, government efforts, and disposable income, contribute to the growth of the industry. Additionally, diabetes and obesity contribute to kidney disorders.

For instance, according to National Institute of Diabetes and Digestive Kidney Diseases, Chronic kidney disease (CKD) affects more than 1 in 7 U.S. adults-an estimated 37 billion Americans.1 For Americans with diabetes or high blood pressure-the two most common causes of kidney disease-the risk for CKD is even greater. Nearly 1 in 3 people with diabetes and 1 in 5 people with high blood pressure have kidney disease.1 Other risk factors for developing kidney disease include heart disease and a family history of kidney failure.

Market Segmentation

By Product Type

Peritoneal Dialysis Solutions

Peritoneal Dialysis Machines

Peritoneal Dialysis Catheters

Dialysis Sets

Others

By Treatment Type

Automated Peritoneal Dialysis (APD)

Continuous Ambulatory Peritoneal Dialysis (CAPD)

By End User

Homecare Settings

Hospitals

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Baxter International Inc, Fresenius Medical Care AG & Co. KGaA, Medtronic plc, Nipro Corporation, DaVita Inc., Diaverum, B. Braun Melsungen AG, Asahi Kasei Corporation, Huaren Pharmaceutical, Co., Ltd, NxStage Medical, Inc among others.

Key Developments

In June 2023, AWAK Technologies (AWAK) and Singapore General Hospital (SGH) announced the launch of a pre-pivotal clinical trial with the enrolment of their first subject to study the safety and efficacy of an improved Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device. AWAK PD is a wearable and ultra-portable peritoneal dialysis (PD) system that allows patients with end-stage kidney disease to have dialysis on the go and has been granted 'Breakthrough Device Designation' by the US Food and Drug Administration (FDA).

Why Purchase the Report?

To visualize the global peritoneal dialysis market segmentation based on product type, treatment type, end user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the peritoneal dialysis market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global peritoneal dialysis market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the prevalence of chronic kidney diseases
    • 4.1.1.2. Rise in the advancements of devices
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of skilled professionals
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Patent Analysis
• 5.6. PESTLE Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Peritoneal Dialysis Solutions*
  • 6.2.1. Introduction
• 6.3. Peritoneal Dialysis Machines
• 6.4. Peritoneal Dialysis Catheters
• 6.5. Dialysis Sets
• 6.6. Others

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment Type
• 7.2. Automated Peritoneal Dialysis (APD)*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Continuous Ambulatory Peritoneal Dialysis (CAPD)

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Homecare Settings*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Hospitals
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. UK
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Baxter International Inc*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Fresenius Medical Care AG & Co. KGaA
• 11.3. Medtronic plc
• 11.4. Nipro Corporation
• 11.5. DaVita Inc.
• 11.6. Diaverum
• 11.7. B. Braun Melsungen AG
• 11.8. Asahi Kasei Corporation
• 11.9. Huaren Pharmaceutical Co., Ltd.
• 11.10. NxStage Medical, Inc (*LIST NOT EXHAUSTIVE)

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us